Use my Search Websuite to scan PubMed, PMCentral, Journal Hosts and Journal Archives, FullText. Kick-your-searchterm to multiple Engines kick-your-query now !>

A dictionary by aggregated review articles of nephrology, medicine and the life sciences Your one-stop-run pathway from word to the immediate pdf of peer-reviewed on-topic knowledge.

10.1016/j.resp.2020.103492 http://scihub22266oqcxt.onion/10.1016/j.resp.2020.103492 32659271!7351052!32659271     free     free     free Warning: file_get_contents(https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&id=32659271&cmd=llinks): Failed to open stream: HTTP request failed! HTTP/1.1 429 Too Many Requests in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 215       Respir+Physiol+Neurobiol 2020 ; 280 (?): 103492 Nephropedia Template TP {{tp|p=32659271|t=2020. Pros and cons of corticosteroid therapy for COVID-19 patients |pdf=|usr=}}{{32659271}} gab.com Text Pros and cons of corticosteroid therapy for COVID-19 patients JO: Respir Physiol Neurobiol http://www.kidney.de/pget.php?&tw=1&pmid=32659271 #FOAvip In December 2019, an outbreak of severe pneumonia was reported in Wuhan, China. Later described as COVID-19 (coronavirus disease 2019), this infection caused by a virus from the Coronaviridae family (SARS-CoV-2) has spread globally. Effective therapies for this new disease are urgently needed. In this short communication, we will evaluate the use of corticosteroids as an adjunctive pharmacological therapy in the management of COVID-19 and describe its pros and cons in light of the latest available evidence. Twit Text FOAVip Pros and cons of corticosteroid therapy for COVID-19 patients ????Respir Physiol Neurobiol http://www.kidney.de/pget.php?&tw=1&pmid=32659271 #FOAvip Twit Text # Free Paper on # # # # # LINK http://www.kidney.de/pget.php?&tw=1&pmid=32659271 #FOAvip English Wikipedia <ref>{{Cite pmid|32659271}}</ref> Pros and cons of corticosteroid therapy for COVID-19 patients #MMPMID32659271 Mattos-Silva P; Felix NS; Silva PL; Robba C; Battaglini D; Pelosi P; Rocco PRM; Cruz FF Respir Physiol Neurobiol 2020[Sep]; 280 (?): 103492 PMID32659271show ga In December 2019, an outbreak of severe pneumonia was reported in Wuhan, China. Later described as COVID-19 (coronavirus disease 2019), this infection caused by a virus from the Coronaviridae family (SARS-CoV-2) has spread globally. Effective therapies for this new disease are urgently needed. In this short communication, we will evaluate the use of corticosteroids as an adjunctive pharmacological therapy in the management of COVID-19 and describe its pros and cons in light of the latest available evidence. |Adrenal Cortex Hormones/administration & dosage/adverse effects[MESH] |Anti-Inflammatory Agents/*administration & dosage/adverse effects[MESH] |Betacoronavirus/*drug effects/physiology[MESH] |COVID-19[MESH] |Coronavirus Infections/blood/*drug therapy/physiopathology[MESH] |Cytokines/*antagonists & inhibitors/blood[MESH] |Dexamethasone/administration & dosage/adverse effects[MESH] |Drug Administration Schedule[MESH] |Glucocorticoids/*administration & dosage/adverse effects[MESH] |Humans[MESH] |Pandemics[MESH] |Pneumonia, Viral/blood/*drug therapy/physiopathology[MESH]Pros and cons of corticosteroid therapy for COVID-19 patients (epmc).pdf DeepDyve Pubget Overpricing